Focused On-demand Library for Golgi-associated plant pathogenesis-related protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9H4G4

UPID:

GAPR1_HUMAN

Alternative names:

Glioma pathogenesis-related protein 2

Alternative UPACC:

Q9H4G4; Q5VZR1; Q8N2S6; Q8WWC9; Q8WX36

Background:

Golgi-associated plant pathogenesis-related protein 1, also known as Glioma pathogenesis-related protein 2, is a protein of interest in the field of molecular biology. Its alternative names suggest a role in plant pathogenesis and possibly in glioma pathogenesis, indicating a multifunctional nature. The protein's specific functions and mechanisms of action remain to be fully elucidated, making it a subject of ongoing research.

Therapeutic significance:

Understanding the role of Golgi-associated plant pathogenesis-related protein 1 could open doors to potential therapeutic strategies. Its involvement in critical biological processes hints at its potential significance in disease mechanisms and therapy development.